



Personal data

Name Olga Petyunina
Date of Birth 17/08/1972
E-mail O_petyunina@ukr.net
Nationality Ukrainian
Address 2A, Liubovi Maloy
avenue, Kharkiv, 61039,
Ukraine
Telephone (057) 373-90-32

Orcid <https://orcid.org/0000-0002-4716-6433>

Postgraduate education

2016-2020 *Doctor of Medical Science*. Thesis title: "Peculiarities of Prognostication of Clinical Outcomes After ST-segment Elevation Myocardial Infarction on the Basis of Left Ventricular Remodeling, Neurohumoral and Proinflammation Activity Evaluation"
2007 *Senior Scientist* (equivalent for Privat-docent), Ukrainian Ministry of Science and Education
2001 *Specialist in Cardiology*, Kharkiv Medical Academy of Postgraduate Education, Ukraine
1997-2000 *PhD in cardiology*. Thesis title: "Digitalis-like Factor and Na-K-ATPase in Patients with Congestive Heart Failure"

Undergraduate education

1989-1995 *General Medicine*, Kharkiv National Medical University, Medical Faculty, Ukraine
1995-1997 *Intership in Therapy*, Kharkiv National Medical University, Ukraine

Training and courses

Courses on pedagogy in the H.S.Skovoroda Kharkiv National

| | |
|------------------|---|
| 2023 | Pedagogical University Implementation and realization of research in treatment of heart failure. |
| 2022 | Sertificate of European Society of Cardiology |
| 2021 | Sport cardiology. Focus on sports ECG and cardiomyopathy. The role of imaging. Sertificate of European Society of Cardiology |
| 2021 | Involving of cardiovascular system on COVID-19 course. Imaging for diagnosis, risk stratification, treatment. Sertificate of European Society of Cardiology |
| 2020 | How to read sports ECG? Sertificate of European Society of Cardiology |
| 2009, 2014, 2019 | <i>Courses in cardiology.</i> Kharkiv Medical Academy of Postgraduate Education, Ukraine |
| 2007, 2016, 2020 | <i>Training in GCP,</i> Certificate «Good Clinical Practice. Clinical trial regulation» in Government Pharmacological Center, Kiev |

Work experience

| | |
|---------------|--|
| 2023 till now | <i>Leading Consultant</i> at the Department of Prevention and Treatment of Emergency Conditions of L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine, Kharkiv. |
| 2005-2023 | <i>Senior Consultant</i> at the Department of Prevention and Treatment of Emergency Conditions of L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine, Kharkiv. |
| 2016 | <i>Associate Professor,</i> Karazin National University, Medical Faculty, Department of Internal and Occupational Diseases. Part-time employment |
| 2000-2005 | <i>Research Fellow</i> at the Department of Prevention and Treatment of Emergency Conditions of L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine, Kharkiv. |

Educational contribution:

| | |
|---------------|--|
| 2023 | <i>Official opponention</i> of PhD student Feldman Diana, topic “Prognostic significance of endothelial monocyte activating polypeptide-II and asymmetric dimethylarginine in the course of acute myocardial infarction in patients with concomitant type 2 diabetes mellitus” |
| 2021 till now | <i>PhD Tutor</i> of Kobets Alla, topic “Prognostic Value of Speckle-Tracking Echocardiography in Appearance of Cardiovascular Events in patients with Myocardial Infarction and Obesity” |
| 2021 | <i>Official opponention</i> of PhD student Pyleva Tetiana, topic: “Peculiarities of Clinical Course and Prognosis in Patients with Stable Ischemic Heart Disease Depending on Mechanism of Ischemia Development ” |
| 2020-till now | <i>Lecturer</i> for PhD students, topic: “Modern Scientific Achievements in Evidence Based Medicine and Good Clinical Practice” |
| 2020-2023 | <i>Lecturer</i> for Ukrainian Doctors, topics: “Anticoagulant Therapy During COVID-19”, “New Oral Anticoagulants in treatment of Heart Failure”, “Kidney Function across Heart Failure”, “Heart failure in patients with Diastolic dysfunction. Review of updates”. |

Clinical experience

I am experienced in the management of patients with a wide spectrum of cardiovascular diseases

Research experience

- *Responsible Executor* of Scientific Themes, National Academy of Medical Science of Ukraine (2011-2019), 2023 till now
- *The Tutor* of Initiative Scientific Theme under National Academy of Medical Science of Ukraine: "Evaluation of Peculiarities of clinical Course of Post-COVID syndrome" (2022 - 2023)
- Academic writing.
- Statistics; descriptive statistics, parametric and nonparametric statistics, survival analysis (Kaplan-Meier, Cox-analyses), ROC-analysis, modelling.
- Scientific data presentation.

Clinical trials experience

Sub-investigator:

- Inform consent agreement
- IWRS;
- Local and Centralized Ethic Committee;
- Investigational product management;
- Study equipment certifications;
- Adverse events assessment, registration and documentation.
- Communication with other specialists in complicated situations.

Clinical trials:

| | |
|---------------|--|
| 2017 till now | High Risk Cardiovascular disease, III phase, sub-investigator |
| 2019 till now | Myocardial Infarction with heart failure, III phase, sub-investigator |
| 2015 till now | Myocardial Infarction, III Phase, sub-investigator |
| 2015-2019 | Chronic kidney disease, Diabetes Mellitus, III phase, sub-investigator |
| 2015-2019 | High Risk Myocardial Infarction, III phase, sub-investigator |
| 2013-2017 | Dyslipidemia, III phase, sub-investigator |
| 2008-2012 | Atrial fibrillation, III Phase, sub-investigator |
| 2009-2011 | Myocardial Infarction, III Phase, sub-investigator |
| 2008-2009 | Hypertension, III phase, sub-investigator |
| 2007-2009 | Myocardial Infarction, III Phase, sub-investigator |
| 2006-2008 | Atrial fibrillation, II Phase, sub-investigator |
| 2003-2005 | Lung Hypertension, III Phase, sub-investigator |
| 2003-2004 | Ischemic Heart Disease, III Phase, sub-investigator |

Invited talks

| | |
|-----------|---|
| 2021-2023 | Heart Failure, Kidney Disease across heart failure, Anticoagulants during COVID-19, the treatment of heart failure with diastolic dysfunction with empagliflozin (Boehringer Ingelheim) |
|-----------|---|

Membership in scientific organizations

2020 – present European Atherosclerosis Society
2014 – present Ukrainian Society of Cardiology

Languages

English (B2), Ukrainian (native speaker), Russian (native speaker).

Publications:

1. Petyunina OV, Kopytsya MP, Berezin AE. Elevated levels of circulating soluble ST2 at discharge predict late adverse ventricular remodeling in patients with ST-segment elevation myocardial infarction. *Biomedical research and therapy*. 2018; 5(12):2863-2875.
2. Petyunina O, Kopytsya M, Kuznetsov I, Vyshnevskaya I. Prognostication of clinical outcomes after STEMI: the role of vascular endothelial growth factor-A. *Georgian medical news*. 2018; (279):79-87.
3. Petyunina O, Kopytsya M, Rudyk Yu, Isayeva G. Promising role of Vascular Endothelial Growth Factor-A in risk stratification after PCI. In: *Vascular Access Surgery*. ed. A.Berezin. London: IntechOpen, 2019:17-134. doi: 10.5772/intechopen.82712
4. Petyunina OV, Kopytsya MP. Risk Factors and endothelin-1 (rs5370) gene polymorphism in patients with myocardial infarction with ST segment elevation. *Мир Медицины и Биологии*. 2019; (68):100-104. doi: 10.26724/2079-8334-2019-2-68-100-104
5. Petyunina O, Kopytsya M, Babichev D, Berezin A. Short-term clinical outcomes in patients with acute myocardial infarction after successful percutaneous coronary revascularization: the role of promoter polymorphism of the endothelial nitric oxide synthase gene. *Biomedical Research and Therapy*. 2019; 6(5):3166-3179. doi.org/10.15419/bmrat.v6i5.543
6. Petyunina OV, Kopytsya MP, Berezin AE. Biomarker-based Prognostication of Adverse Cardiac Remodeling after STEMI: the Role of Single Nucleotide Polymorphism T786C in Endothelial NO-synthase gene. *Journal of Cardiol Ther*. 2019; 6(1):768-774. doi:10.17554/j.issn.2309-6861.2019.06.165
7. Petyunina OV, Kopytsya MP, Berezin AE. Prognostication of Late Cardiac Remodeling in Patients With STEMI Underwent Successful Percutaneous Coronary Intervention: the Role of Macrophage Inhibitory Factor. *Journal of Cardiol Ther*. 2019; 6(1):1-8 doi: 10.17554/j.issn.2309-6861.2019.06.166
8. Petyunina OV, Kopytsya M P, Berezin AE, Skrynnyk OV The role of Val66Met single nucleotide polymorphism in brain-derived neurotropic factor gene in prediction of adverse outcomes after ST-segment elevation myocardial infarction. *Heart and Mind*. 2019; 3(1): 7-14.
9. Petyunina OV, Kopytsya MP, Berezin AE Macrophage Inhibitory Factor Predicted Late Cardiac Remodeling in Acute Myocardial Infarction Patients Underwent Successful Percutaneous Coronary Intervention. *La Prensa Medica Argentina*. 2019; 105(5):160.
10. Petyunina OV, Kopytsya MP, Berezin AE The Utility of New Biomarker-based Predictive Model for Clinical Outcomes Among ST-elevation Myocardial Infarction Patients. *The open biomarkers journal*. 2020; 10:23-37. DOI: 10.2174/1875318302010010023

11. Petyunina OV, Kopytsya MP, Berezin AE, Skrynnyk OV Subclinical emotional distress predicts 6-month clinical outcomes after ST-segment elevation myocardial infarction. *Future Cardiology*. Published Online: 8 Jun 2020. <https://doi.org/10.2217/fca-2019-0082>
12. Petyunina OV, Kopytsya MP, Berezin AE Brain-derived neurotrophic factor gene polymorphism in post-ST-elevation myocardial infarction patients undergoing primary percutaneous intervention. *Biomedical research and therapy*. Published Online: Aug 31 2020. Doi: 10.15419/bmrat.v7i8.622
13. Isayeva AS, Vovchenko MN, Petyunina OV Sedentary Lifestyle Attenuates Positive Metabolic Effect of Regular Physical Exercise. *Journal of Endocrinology and Metabolism. North America*, 0, mar 2022. Available at <<https://jofem.org/index.php/jofem/article/view/797/284284570>>. Date accessed: 27 Mar. 2022.
14. Berezina, T.A.; Kopytsya, M.P.; Petyunina, O.V.; Berezin, A.A.; Obradovic, Z.; Schmidbauer, L.; Lichtenauer, M.; Berezin, A.E. Lower Circulating Cell-Free Mitochondrial DNA Is Associated with Heart Failure in Type 2 Diabetes Mellitus Patients. *Cardiogenetics* 2023, 13, 15–30. <https://doi.org/10.3390/cardiogenetics13010003>
15. Petyunina O., Kopytsya M., Kobets A., Berezin A. Myocardial Mechanical Dispersion Predicts Adverse Cardiac Remodeling in Patients with ST Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention. *Archives of the Turkish society of cardiology*. -2023. 5(2):119-128. DOI:10.5543/tkda.2022.31531
16. Vyshnevskaya I, Petyunina O, Kopytsya M, Bilchenko A, Peteneva L. THE ROLE OF BIOCHEMICAL MARKERS AND PATIENT-REPORTED OUTCOMES IN PREDICTING COMPOSITE ONE-YEAR ENDPOINT IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION *Polish Medical Journal*. -2023. 1:21-30. DOI: 10.36740/Merkur202301103

Scientific grants

- | | |
|-----------|---|
| 2011-2013 | “New Biomarkers to Improve the Accuracy of Prognosis and Definition of Treatment of Acute Coronary Syndrome (Government Registered Number 0111U0011257); Grant of the National Academy of Medical Science of Ukraine (equivalent to 50 000 EURO) |
| 2014-2016 | “Establishment of Modern Models of Risk Stratification and Evaluation of Personalized Prophylactic Measures of Sudden Cardiac Death Appearance After Acute Coronary Syndrome” (Government Registered Number 0114U001167), Grant of the National Academy of Medical Science of Ukraine (equivalent to 50 000 EURO), |
| 2017-2019 | “Evaluation of Biochemical, Genetic mechanisms of Reperfusion Damage of Myocardium and Estimate the Cardioprotective Effect of Antiplatelet Therapy in Patients with Acute Myocardial Infarction (Government registered Number 0117U003028), Grant of the National Academy of Medical Science of Ukraine (equivalent to 50 000 EURO), |